Oxford Gene Technology Grants Microarray License to Aushon Biosystems
News Jun 13, 2007
Oxford Gene Technology (OGT) and Aushon BioSystems have announced the completion of a licence agreement granting Aushon access to OGT’s “Southern array patents”, the fundamental patents covering the manufacture and marketing of oligonucleotide microarrays.
The granted license will enable Aushon BioSystems to manufacture and sell oligonucleotide microarrays, worldwide, and to perform services based on oligonucleotide arrays.
Sue Sutton, Vice President Licensing North America, at OGT said: “Successful discussions with Aushon have concluded with the granting of this license. This will enable them to extend their current offering to provide a range of microarray products to the market.”
John Austin, President and Co-Founder at Aushon BioSystems added: “This agreement will enable Aushon to provide high quality, flexible and affordable oligonucleotide microarray products to our customers in life science research, drug discovery/development, and clinical diagnostics."
The licence will remain valid for the patents’ lifetime. Financial details were not disclosed.
Massachusetts General Hospital (MGH) researchers have found that extracellular RNA (exRNA) in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.READ MORE
Is there a link between differences in IQ test performance and the activity of certain genes? Researchers have shown that modifications in the structure of a specific gene have a negative impact on individual test performance. This suggests that environmentally-induced epigenetic changes to our genetic material have a greater impact on intelligence than previously thought.